Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)
In a report released today, Miki Sogi from Bernstein maintained a Hold rating on Astellas Pharma, with a price target of Yen2,000.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sogi covers the Healthcare sector, focusing on stocks such as Chugai Pharmaceutical Co, Astellas Pharma, and Shionogi & Co. According to TipRanks, Sogi has an average return of 1.7% and a 48.28% success rate on recommended stocks.
In addition to Bernstein, Astellas Pharma also received a Hold from Citi’s Hidemaru Yamaguchi in a report issued today. However, on January 25, TipRanks – xAI reiterated a Buy rating on Astellas Pharma (Other OTC: ALPMF).
The company has a one-year high of Yen2,335.50 and a one-year low of Yen1,243.50. Currently, Astellas Pharma has an average volume of 8.02M.
Read More on ALPMF:
Disclaimer & DisclosureReport an Issue
- Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
- Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
- ALPMF Upcoming Earnings Report: What to Expect?
- Astellas Targets Post‑Stroke Recovery With First‑in‑Human ASP2246 Study
- Astellas Completes Key Menopause Drug Study in Japan, Setting Up Next Growth Phase for Fezolinetant
